Company profile OCGN

Ocugen Inc
ocugen, inc., is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. the company’s lead programs in ocular graft versus host disease (ocu300) and chronic dry eye disease (ocu310) are expected to enter pivotal clinical trials in 2018. ocu300 received the first and only orphan dr...ug designation for ocular graft versus host disease, providing certain regulatory and economic benefits. ocugen is also developing novel biologic therapies for retinitis pigmentosa (ocu100) and wet amd (ocu200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (ocu400). for more information, please visit www.ocugen.com. Show More
Quarter analysis & expected interest

There is not enough data for ocugen -stock -company to provide analysis

Correlation between past revenue and ocugen -stock -company search interest

There is not enough data for ocugen -stock -company to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ocugen -stock -company to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for gene therapy for blindness -stock to provide analysis

Correlation between past revenue and gene therapy for blindness -stock search interest

There is not enough data for gene therapy for blindness -stock to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for gene therapy for blindness -stock to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 00:50:12.

After 38 days of this quarter the interest is at 34.0. Based on that we can calculate that during remaining 53 days it will total up to 81.0.
retinitis pigmentosa treatment expected interest is significantly lower compared to previous quarter (-79.8%) and same quarter last year (-85.2%).

YearQ1Q2Q3Q4
201989
300
237.1% QoQ
262
-12.7% QoQ
284
8.4% QoQ
2020 318
257.3% YoY 12.0% QoQ
127
-57.7% YoY -60.1% QoQ
217
-17.2% YoY 70.9% QoQ
229
-19.4% YoY 5.5% QoQ
2021 205
-35.5% YoY -10.5% QoQ
193
52.0% YoY -5.9% QoQ
355
63.6% YoY 83.9% QoQ
580
153.3% YoY 63.4% QoQ
2022 424
106.8% YoY -26.9% QoQ
413
114.0% YoY -2.6% QoQ
360
1.4% YoY -12.8% QoQ
379
-34.7% YoY 5.3% QoQ
2023 548
29.2% YoY 44.6% QoQ
437
5.8% YoY -20.3% QoQ
153
-57.5% YoY -65.0% QoQ
401
5.8% YoY 162.1% QoQ
2024 34
-93.8% YoY -91.5% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and retinitis pigmentosa treatment search interestLast update: February 08 2024 00:50:12.
Correlation coefficient between keyword and revenue is -0.72
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 00:50:12.

The average 5 years interest of retinitis pigmentosa treatment was 24.26 per week.
The last year interest of retinitis pigmentosa treatment compared to the last 5 years has changed by 13.52%.
The interest for retinitis pigmentosa treatment is seasonal.
The last year interest is quite higher compared to 5 years ago. It has increased by 30.34%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for leber congenital amaurosis cure to provide analysis

Correlation between past revenue and leber congenital amaurosis cure search interest

There is not enough data for leber congenital amaurosis cure to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for leber congenital amaurosis cure to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 00:50:15.

After 38 days of this quarter the interest is at 107.0. Based on that we can calculate that during remaining 53 days it will total up to 256.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019112
185
65.2% QoQ
221
19.5% QoQ
53
-76.0% QoQ
2020 18
-83.9% YoY -66.0% QoQ
102
-44.9% YoY 466.7% QoQ
93
-57.9% YoY -8.8% QoQ
181
241.5% YoY 94.6% QoQ
2021 142
688.9% YoY -21.5% QoQ
232
127.5% YoY 63.4% QoQ
219
135.5% YoY -5.6% QoQ
108
-40.3% YoY -50.7% QoQ
2022 60
-57.7% YoY -44.4% QoQ
28
-87.9% YoY -53.3% QoQ
121
-44.7% YoY 332.1% QoQ
278
157.4% YoY 129.8% QoQ
2023 197
228.3% YoY -29.1% QoQ
361
1189.3% YoY 83.2% QoQ
328
171.1% YoY -9.1% QoQ
194
-30.2% YoY -40.9% QoQ
2024 107
-45.7% YoY -44.8% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and dry AMD treatment search interestLast update: February 08 2024 00:50:15.
Correlation coefficient between keyword and revenue is -0.52
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 00:50:15.

The average 5 years interest of dry AMD treatment was 12.85 per week.
The last year interest of dry AMD treatment compared to the last 5 years has changed by 72.84%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 96.03%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 10:43:34.

After 39 days of this quarter the interest is at 94.0. Based on that we can calculate that during remaining 52 days it will total up to 219.0.
diabetic macular edema treatment expected interest is significantly higher compared to previous quarter (+271.2%) but similar to same quarter last year.

YearQ1Q2Q3Q4
201956
0
-100.0% QoQ
202
inf% QoQ
279
38.1% QoQ
2020 55
-1.8% YoY -80.3% QoQ
203
inf% YoY 269.1% QoQ
58
-71.3% YoY -71.4% QoQ
137
-50.9% YoY 136.2% QoQ
2021 57
3.6% YoY -58.4% QoQ
50
-75.4% YoY -12.3% QoQ
60
3.4% YoY 20.0% QoQ
109
-20.4% YoY 81.7% QoQ
2022 262
359.6% YoY 140.4% QoQ
116
132.0% YoY -55.7% QoQ
73
21.7% YoY -37.1% QoQ
167
53.2% YoY 128.8% QoQ
2023 250
-4.6% YoY 49.7% QoQ
174
50.0% YoY -30.4% QoQ
69
-5.5% YoY -60.3% QoQ
59
-64.7% YoY -14.5% QoQ
2024 94
-62.4% YoY 59.3% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and diabetic macular edema treatment search interestLast update: February 09 2024 10:43:33.
Correlation coefficient between keyword and revenue is 0.09
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 10:43:45.

The average 5 years interest of diabetic macular edema treatment was 9.69 per week.
The last year interest of diabetic macular edema treatment compared to the last 5 years has changed by 8.36%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by -4.72%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 15:45:06.

After 39 days of this quarter the interest is at 135.0. Based on that we can calculate that during remaining 52 days it will total up to 315.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019121
285
135.5% QoQ
274
-3.9% QoQ
352
28.5% QoQ
2020 300
147.9% YoY -14.8% QoQ
290
1.8% YoY -3.3% QoQ
296
8.0% YoY 2.1% QoQ
293
-16.8% YoY -1.0% QoQ
2021 202
-32.7% YoY -31.1% QoQ
286
-1.4% YoY 41.6% QoQ
252
-14.9% YoY -11.9% QoQ
377
28.7% YoY 49.6% QoQ
2022 309
53.0% YoY -18.0% QoQ
354
23.8% YoY 14.6% QoQ
245
-2.8% YoY -30.8% QoQ
314
-16.7% YoY 28.2% QoQ
2023 420
35.9% YoY 33.8% QoQ
328
-7.3% YoY -21.9% QoQ
305
24.5% YoY -7.0% QoQ
326
3.8% YoY 6.9% QoQ
2024 135
-67.9% YoY -58.6% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and diabetic retinopathy treatment search interestLast update: February 09 2024 15:45:06.
Correlation coefficient between keyword and revenue is 0.29
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 15:45:07.

The average 5 years interest of diabetic retinopathy treatment was 23.23 per week.
The last year interest of diabetic retinopathy treatment compared to the last 5 years has changed by 14.72%.
The interest for diabetic retinopathy treatment is seasonal.
The last year interest is quite higher compared to 5 years ago. It has increased by 17.66%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 00:50:27.

After 38 days of this quarter the interest is at 88.0. Based on that we can calculate that during remaining 53 days it will total up to 211.0.
wet AMD treatment expected interest is significantly higher compared to same quarter last year (+42.6%) but similar to previous quarter.

YearQ1Q2Q3Q4
20190
133
inf% QoQ
134
0.8% QoQ
160
19.4% QoQ
2020 122
inf% YoY -23.8% QoQ
65
-51.1% YoY -46.7% QoQ
112
-16.4% YoY 72.3% QoQ
158
-1.2% YoY 41.1% QoQ
2021 77
-36.9% YoY -51.3% QoQ
36
-44.6% YoY -53.2% QoQ
118
5.4% YoY 227.8% QoQ
153
-3.2% YoY 29.7% QoQ
2022 76
-1.3% YoY -50.3% QoQ
152
322.2% YoY 100.0% QoQ
147
24.6% YoY -3.3% QoQ
295
92.8% YoY 100.7% QoQ
2023 148
94.7% YoY -49.8% QoQ
582
282.9% YoY 293.2% QoQ
299
103.4% YoY -48.6% QoQ
220
-25.4% YoY -26.4% QoQ
2024 88
-40.5% YoY -60.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and wet AMD treatment search interestLast update: February 08 2024 00:50:27.
Correlation coefficient between keyword and revenue is -0.44
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 00:50:27.

The average 5 years interest of wet AMD treatment was 12.6 per week.
The last year interest of wet AMD treatment compared to the last 5 years has changed by 99.92%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 166.28%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ocugen pipeline to provide analysis

Correlation between past revenue and ocugen pipeline search interest

There is not enough data for ocugen pipeline to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ocugen pipeline to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ocugen gene therapy. to provide analysis

Correlation between past revenue and ocugen gene therapy. search interest

There is not enough data for ocugen gene therapy. to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ocugen gene therapy. to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for OCGN
Earnings date: 2024-02-26 After close
Company name: Ocugen Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-14T20:30:00Z

GlobeNewswire
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes

2026-05-13T11:02:00Z

GlobeNewswire
Ocugen to Participate in Upcoming May Scientific and Investor Conferences

2026-05-05T12:32:54Z

GlobeNewswire
Ocugen Provides Business Update with First Quarter 2026 Financial Results

2026-05-05T12:12:21Z

GlobeNewswire
Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

2026-05-04T20:01:51Z

GlobeNewswire
Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

2026-04-29T11:02:00Z

GlobeNewswire
Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results

2026-04-23T11:02:00Z

GlobeNewswire
Ocugen to Present at April 2026 Investor and Industry Conferences

2026-04-10T09:55:00-04:00

PR Newswire
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells

2026-04-01T11:02:00Z

GlobeNewswire
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

2026-03-25T10:59:52Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Ocugen, Raises Price Target to $10

2026-03-24T11:45:00Z

GlobeNewswire
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

2026-03-23T11:02:00Z

GlobeNewswire
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

2026-03-17T13:44:50Z

Analyst Upgrades
Canaccord Genuity Initiates Coverage On Ocugen with Buy Rating, Announces Price Target of $12

2026-03-11T11:54:10Z

Analyst Upgrades
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday

2026-03-11T11:38:49Z

Analyst Upgrades
Oppenheimer Initiates Coverage On Ocugen with Outperform Rating, Announces Price Target of $10